Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.66 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.64 |
| ▸ | WNT3A | P56704 | 5/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8557156 | 0.95 | ADAM17 (0.68) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL9048121 | 0.89 | ADAM17 (0.71) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL12838313 | 0.86 | ADAM17 (0.68) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL1563151 | 0.85 | GABRA1 (0.74) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL5981843 | 0.85 | ADAM17 (0.66) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL3717752 | 0.84 | ADAM17 (0.68) | ADAM17CTNNB1WNT3AGPR84LMNA | |
| SCHEMBL8959866 | 0.84 | GABRA1 (0.72) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL8960008 | 0.84 | GABRA1 (0.72) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL8959628 | 0.84 | GABRA1 (0.72) | ADAM17CTNNB1WNT3AGABRA1GABRB2 | |
| SCHEMBL8077164 | 0.84 | GABRA1 (0.72) | ADAM17CTNNB1WNT3AGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | ALZHEIMER'S INSTITUTE OF AMERICA (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2739144-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Alzheimer's Institute of America, Inc. (US) | 2014-06-11 | — | — | EP | disclosed |
| WO-2012177782-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7462628-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-09 | — | — | US | disclosed |
| US-7138533-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-21 | — | — | US | disclosed |
| US-7132547-B2 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-07 | — | — | US | disclosed |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ISHIHARA YUJI | 2006-09-21 | — | — | US | disclosed |
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-23 | — | — | US | disclosed |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-09-08 | — | — | US | disclosed |
| CN-1589153-A | Prevention or treatment of urinary disorders | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-03-02 | — | — | CN | disclosed |
| EP-1466625-A1 | PREVENTIVES/REMEDIES FOR URINARY DISTURBANCE | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063769-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | ADAM17 407/4885CTNNB1 2598/4885WNT3A 3076/4885 |
| US-20140349989-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | NFATC1, CD4, CD47 | ADAM17 3711/4885CTNNB1 3068/4885WNT3A 1518/4885 |
| US-20050197362-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, CHRM1 | ADAM17 407/4885CTNNB1 2598/4885WNT3A 3076/4885 |
| US-20060211675-A1 | Preventives/remedies for urinary disturbance | ACHE, BPHL, ACE | ADAM17 438/4885CTNNB1 4153/4885WNT3A 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.